In a historic shift for the American healthcare landscape, five of the world’s leading pharmaceutical companies Novartis, Amgen, Gilead Sciences, GSK, and Sanofi announced coordinated agreements with the U.S. government on December 19, 2025. The voluntary “Most Favored Nation” (MFN) pricing deals aim to lower prescription costs for millions of Americans while triggering over $150 billion in domestic manufacturing and R&D investments.
The agreements come in response to President Trump’s July 31 mandate, which challenged the industry to align U.S. drug prices with the lowest rates available in other high-income nations.
The “Most Favored Nation” Strategy
The core of these agreements is the transition to a “Most Favored Nation” pricing model. This ensures that the U.S. no longer pays significantly more for the same innovative medicines than peer countries such as Germany, France, and Japan.
Key pillars of the deals include:
- Global Price Parity: Future and select current medicines will be launched or adjusted to match international benchmarks.
- The TrumpRx Platform: A new direct-to-patient portal (TrumpRx.gov) will launch in January 2026, allowing patients to bypass insurance and pharmacy benefit managers (PBMs) to buy drugs at steep cash discounts.
- The GENEROUS Model: Participation in the GENErating cost Reductions fOr U.S. Medicaid (GENEROUS) initiative, providing supplemental rebates to state Medicaid programs to ensure they receive the lowest global prices.
Company-Specific Breakthroughs
Novartis: Medicaid Reform and Direct Access
Novartis has committed to launching future medicines with global price parity and will make Mayzent® (Multiple Sclerosis), Rydapt® (Leukemia), and Tabrecta® (Lung Cancer) available on TrumpRx. Notably, Mayzent’s price is expected to drop from nearly $10,000 to approximately $1,137 for direct purchasers. CEO Vas Narasimhan highlighted a $23 billion investment plan, including a new $1.1 billion research hub in San Diego and a flagship manufacturing center in North Carolina.
Amgen: Major Discounts on Chronic Care
Amgen is expanding its AmgenNow™ program to provide Aimovig® (migraine) and Amjevita® (biosimilar Humira) at a discounted monthly price of $299—representing cuts of up to 80% from current list prices. These will also be available on TrumpRx alongside the cholesterol drug Repatha®, priced at $239.
Gilead Sciences: Ending the “Global Freeloading”
Gilead’s agreement targets HIV, Hepatitis C, and COVID-19 treatments. Most significantly, the Hepatitis C cure Epclusa® will see its price tag slashed from $24,920 to $2,425 for patients using TrumpRx. Gilead also confirmed a $32 billion five-year investment in U.S. manufacturing, projected to create 3,000 jobs.
GSK: Relief for 40 Million Respiratory Patients
GSK will lower prices across its respiratory portfolio by up to 66%. The popular asthma inhaler Advair Diskus 500/50 will drop from $265 to $89 on the TrumpRx platform. GSK also joined the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR), agreeing to secure a U.S. reserve of albuterol to protect the supply chain.
Sanofi: $35 Insulin and 70% Savings
Sanofi is aligning Medicaid prices for diabetes, cardiovascular, and cancer drugs with international benchmarks, yielding an average reduction of 61%. Furthermore, all Sanofi insulin products will be listed on TrumpRx at a flat $35 per month, while the blood thinner Plavix® will be available for just $16.
The Grand Bargain: Innovation for Tariffs
In exchange for these price reductions and massive domestic investments, the U.S. government is granting these companies a three-year reprieve from Section 232 pharmaceutical tariffs. This “innovation-for-access” trade-off is designed to strengthen national health security by bringing the supply chain back to American soil.
With 14 of the 17 largest drug manufacturers now signed on to similar deals, the administration’s MFN policy is poised to redefine the economics of the pharmaceutical industry starting in early 2026.
Last Modified:
Graduated from the University of Kerala with B.Sc. Botany and Biotechnology. Attained Post-Graduation in Biotechnology from the Kerala University of Fisheries and Ocean Science (KUFOS) with the third rank. Conducted various seminars and attended major Science conferences. Done 6 months of internship in ICMR – National Institute of Nutrition, Hyderabad. 5 years of tutoring experience.
